Evidence map›Paper›PMID 42743450›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2026

EBNA1

Dries De Wit, Jarne Beliën, Margaux David, Stijn Swinnen, Nina Dedoncker, Lidia Yshii, Bénédicte Dubois

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dries De WitLaboratory for Neuroimmunology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.ORCID 0000-0001-7992-9784
Jarne BeliënLaboratory for Neuroimmunology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.ORCID 0000-0001-6731-6649
Margaux DavidLaboratory for Neuroimmunology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.ORCID 0000-0001-7806-8417
Stijn SwinnenLaboratory for Neuroimmunology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.ORCID 0000-0003-1028-197X
Nina DedonckerLaboratory for Neuroimmunology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.
Lidia YshiiLaboratory for Neuroinflammation, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.ORCID 0000-0002-1988-6855
Bénédicte DuboisLaboratory for Neuroimmunology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.ORCID 0000-0003-0604-8702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesInfection with the Epstein-Barr virus is a prerequisite for the development of multiple sclerosis (MS). Recent evidence has identified an antibody response against a peptide region of the Epstein-Barr virus nuclear antigen-1 (EBNA1

methodsIn this cross-sectional study, we quantified IgG reactivity against 4 20-mer peptides in the EBNA1

resultsWe observed an increased antibody response to EBNA1 DISCUSSION: Our findings contribute to the accumulating evidence of a role for EBNA1

Indexed as

Antibodies, ViralEpstein-Barr Virus Nuclear AntigensImmunoglobulin GMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingAdultAutoantibodiesAutoantigensCross ReactionsCross-Sectional StudiesFemaleHumansMaleMiddle AgedAntibodies, ViralAutoantibodiesAutoantigensEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensImmunoglobulin G

Identifiers

PMID42743450
PMCPMC13580138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.